Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Finance > Eyecare company Alcon's shares plunge on revised 2025 outlook
    Finance

    Eyecare company Alcon's shares plunge on revised 2025 outlook

    Published by Global Banking & Finance Review®

    Posted on May 14, 2025

    2 min read

    Last updated: January 23, 2026

    Image illustrating K+S's Q2 financial report, showing a decline in revenue and sales volume due to logistical challenges. Relevant to banking and finance news.
    K+S revenue report highlights Q2 revenue miss and sales volume drop - Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Quick Summary

    Alcon's shares dropped 9.4% after revising its 2025 outlook, citing U.S. tariffs. The company reported lower-than-expected revenue and net income.

    Alcon Shares Drop on Revised 2025 Outlook and Tariff Impact

    By Anastasiia Kozlova

    (Reuters) -Swiss eye care group Alcon's shares fell sharply on Wednesday after the company revised its 2025 outlook to reflect the impact of U.S. tariffs and as it reported first-quarter results below estimates.

    Late on Tuesday, Alcon raised its 2025 sales forecast to between $10.4 and $10.5 billion on FX tailwinds, up from its earlier projection of $10.2 to $10.4 billion, but lowered its core operating margin outlook to 20–21%, down from the 21–22% expected in February.

    Alcon's shares were down 9.4% at 0708 GMT, on track for their worst day since March 2020.

    "This outlook incorporates a gross tariff impact of approximately $80 million, which is expected to pressure cost of net sales," the company said in a statement, adding that it planned to fully offset the impact through operational measures and currency effects.

    Some analysts had expected Alcon to maintain its guidance or even upgrade it.

    Alcon's shares had dropped about 15% early April, reacting to President Donald Trump's tariff announcement and the subsequent response from China.

    The company, which produces contact lenses, dry eye drops, gels and other related products, also reported quarterly revenue of $2.45 billion, slightly below analysts' average forecast of $2.51 billion, based on LSEG data.

    It reported net income of $350 million, missing market expectations of $377.7 million.

    (Reporting by Anastasiia Kozlova in Gdansk. Editing by Jane Merriman)

    Key Takeaways

    • •Alcon shares fell 9.4% after revising its 2025 outlook.
    • •The company adjusted its sales forecast due to FX tailwinds.
    • •Core operating margin outlook was lowered to 20-21%.
    • •U.S. tariffs are expected to impact net sales by $80 million.
    • •Quarterly revenue and net income missed analysts' expectations.

    Frequently Asked Questions about Eyecare company Alcon's shares plunge on revised 2025 outlook

    1What is the main topic?

    The article discusses Alcon's share price drop following a revised 2025 outlook due to U.S. tariffs and lower-than-expected financial results.

    2Why did Alcon's shares drop?

    Alcon's shares dropped due to a revised 2025 outlook reflecting U.S. tariffs and financial results below market expectations.

    3What financial results did Alcon report?

    Alcon reported quarterly revenue of $2.45 billion and net income of $350 million, both below analysts' forecasts.

    More from Finance

    Explore more articles in the Finance category

    Image for Russia launches massive attack on Ukraine's energy system, Zelenskiy says
    Russia launches massive attack on Ukraine's energy system, Zelenskiy says
    Image for Russia launched 400 drones, 40 missiles to hit Ukraine's energy sector, Zelenskiy says
    Russia launched 400 drones, 40 missiles to hit Ukraine's energy sector, Zelenskiy says
    Image for The Kyiv family, with its pets and pigs, defying Russia and the cold
    The Kyiv family, with its pets and pigs, defying Russia and the cold
    Image for Two Polish airports reopen after NATO jets activated over Russian strikes on Ukraine
    Two Polish airports reopen after NATO jets activated over Russian strikes on Ukraine
    Image for French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    Image for Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Image for Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Image for Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Image for Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Image for Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Image for Big Tech's quarter in four charts: AI splurge and cloud growth
    Big Tech's quarter in four charts: AI splurge and cloud growth
    Image for EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    View All Finance Posts
    Previous Finance PostBarclays, Goldman raise STOXX 600 targets as trade truce eases recession fears
    Next Finance PostTime to suffocate Russia's economy after 17th EU sanctions package, France says